Max Mano

Summary

Country: UK

Publications

  1. ncbi Remaining controversies in the upfront management of advanced ovarian cancer
    M S Mano
    Unite de Chimiotherapie, Institut Jules Bordet, Brussels, Belgium
    Int J Gynecol Cancer 14:707-20. 2004
  2. ncbi Locally advanced breast cancer in octogenarian women
    Max Mano
    Beatson Oncology Centre, Glasgow, UK
    Breast Cancer Res Treat 89:81-90. 2005
  3. ncbi Liver metastases from breast cancer: management of patients with significant liver dysfunction
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6TN, UK
    Cancer Treat Rev 31:35-48. 2005
  4. ncbi Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    Cancer Treat Rev 31:69-78. 2005
  5. ncbi Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow, UK
    Breast 15:117-8. 2006
  6. ncbi Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy
    Max Mano
    Institut Jules Bordet, Rue Héger Bordet 01, 1000 Bruxelles, Belgium
    Cancer Treat Rev 32:106-18. 2006
  7. ncbi Management of breast cancer in patients prenatally exposed to diethylstilbestrol: are we prepared?
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Rd, Glasgow G11 6NT, UK
    Breast 14:408-10. 2005
  8. ncbi Colon cancer: update on adjuvant therapy
    Max S Mano
    Medical Oncology Unit, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Clin Colorectal Cancer 7:178-83. 2008
  9. ncbi Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer
    Max Mano
    Department of Medical Oncology at the Saint Luc University Clinics, Brussels, Belgium
    Nat Clin Pract Oncol 5:415-25. 2008
  10. ncbi Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002
    Angelo Di Leo
    Department of Chemotherapy, Jules Bordet Institute, Brussels, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Int J Clin Oncol 7:245-53. 2002

Detail Information

Publications13

  1. ncbi Remaining controversies in the upfront management of advanced ovarian cancer
    M S Mano
    Unite de Chimiotherapie, Institut Jules Bordet, Brussels, Belgium
    Int J Gynecol Cancer 14:707-20. 2004
    ..In this article, we review the rationale behind these controversial issues, and provide the levels of evidence supporting the current recommendations for AOC management...
  2. ncbi Locally advanced breast cancer in octogenarian women
    Max Mano
    Beatson Oncology Centre, Glasgow, UK
    Breast Cancer Res Treat 89:81-90. 2005
    ..This article reviews the current evidence, options, and most promising approaches for these patients...
  3. ncbi Liver metastases from breast cancer: management of patients with significant liver dysfunction
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6TN, UK
    Cancer Treat Rev 31:35-48. 2005
    ..In this paper, we review the optimal doses of cytotoxics used in this clinical situation and provide some tips on the management of these patients, based on the limited data currently available in the literature...
  4. ncbi Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    Cancer Treat Rev 31:69-78. 2005
    ..Unfortunately, as research is moving towards other more important questions, many of these uncertainties may never be clarified. In this paper, we review the current evidence behind some of the most commonly used anthracycline schedules...
  5. ncbi Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow, UK
    Breast 15:117-8. 2006
    ..This is particularly well documented with paclitaxel, but may also be the case with docetaxel...
  6. ncbi Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy
    Max Mano
    Institut Jules Bordet, Rue Héger Bordet 01, 1000 Bruxelles, Belgium
    Cancer Treat Rev 32:106-18. 2006
    ..There are still a number of unanswered questions that will have to be addressed by properly designed, adequately powered randomised clinical trials...
  7. ncbi Management of breast cancer in patients prenatally exposed to diethylstilbestrol: are we prepared?
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Rd, Glasgow G11 6NT, UK
    Breast 14:408-10. 2005
    ..We report on the interesting example of a young woman with a history of vaginal adenosis, who was also diagnosed with early breast cancer...
  8. ncbi Colon cancer: update on adjuvant therapy
    Max S Mano
    Medical Oncology Unit, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium
    Clin Colorectal Cancer 7:178-83. 2008
    ..Finally, as we might have reached a plateau in terms of cytotoxic chemotherapy, numerous clinical trials are now focusing on the role of biologic agents in the adjuvant setting...
  9. ncbi Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer
    Max Mano
    Department of Medical Oncology at the Saint Luc University Clinics, Brussels, Belgium
    Nat Clin Pract Oncol 5:415-25. 2008
    ....
  10. ncbi Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002
    Angelo Di Leo
    Department of Chemotherapy, Jules Bordet Institute, Brussels, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Int J Clin Oncol 7:245-53. 2002
    ..In the last part of the article, the most important findings have been summarized and future avenues of research have been outlined...
  11. ncbi Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma
    Daniela D Rosa
    Department of Medicine, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Arch Gynecol Obstet 278:457-62. 2008
    ..We present data from heavily pretreated patients to whom the folinic acid, 5-fluorouracil and oxaliplatin (Folfox) regimen was administered. The objectives were to assess response rate and to evaluate the safety profile...
  12. ncbi The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours
    Max S Mano
    Medical Oncology Unit, Jules Bordet Institut, Bd de Waterloo, 125, 1000 Brussels, Belgium
    Cancer Treat Rev 33:64-77. 2007
    ..The prognostic significance of T2A aberrations is currently unknown...
  13. ncbi Novel cytotoxic drugs: old challenges, new solutions
    Gustavo F V Ismael
    Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, Belgium
    Cancer Treat Rev 34:81-91. 2008
    ..In this review we highlight the development of promising novel cytotoxic drugs that will hopefully offer not only gains in efficacy, but also in safety, tolerability and convenience in the treatment of patients with cancer...